This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

15 Jul 2011

Catalent Licenses CR Tableting Tech from Sanwa

This technology expands Catalent’s capabilities in designing pulsatile targeted drug delivery, immediate and extended release combination tablets, and combination product tablets containing multiple active drugs.

Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have signed an exclusive agreement to bring OSDrC, Sanwa’s drug delivery tableting technology, to global markets.


OSDrC has commercially marketed by Sanwa in Japan. Catalent will market OSDrC in all markets outside of Japan, Korea, China (Hong Kong), and Taiwan. Catalent will utilize its global footprint, modified release delivery expertise, and integrated manufacturing know-how to bring OSDrC to the global market. Catalent plans to commence customer product development trials at its Winchester, KY facility in January, 2012.


OSDrC enables the design of single or multi-core tablets, "with a practically endless variety of core numbers, s

Related News